Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Study Summary

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805

Conditions

Non-Small Cell Lung Cancer, NSCLC KRAS, NRAS, HRAS-mutated NSCLC KRAS G12C-mutated Solid Tumors, Lung Cancer Lung Cancer Stage IV, Advanced Solid Tumor, Cancer RAS G12D-mutated NSCLC

Interventions / Drugs

RMC-6291 RMC-6236 Pembrolizumab Cisplatin Carboplatin Pemetrexed RMC-9805

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment616 participants

Primary Completion—

Lead SponsorRevolution Medicines, Inc.

Data Retrieved2026-04-11 04:26:28.070686+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.